Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Biognosys: Beat Lüthi

Swiss proteomics firm Biognosys has appointed Beat Lüthi as board director. Lüthi is CEO of CTC Analytics, a privately held Swiss laboratory automation and sample handling technology company. He is also chairman of the board of Inficon Group; vice chairman of Straumann Group; and a board member at Skan AG. He holds an MSc in electrical engineering and a PhD in business administration from ETH Zurich.

Metabolon: Sean Iverson

Metabolon has appointed Sean Iverson as VP of global marketing. Iverson joins the company from Sophia Genetics, where he served as VP of global marketing. He has also held leadership roles with Danaher and Cisco Systems. Iverson holds an MBA in international marketing from the Leavey School of Business at Santa Clara University, a master's degree in international relations from Johns Hopkins University School of Advanced International Studies, and a bachelor's degree political science and Asian studies from Brigham Young University.

Pacific Biosciences: Peter Fromen

Pacific Biosciences Chief Commercial Officer Peter Fromen has notified the company of his intention to resign, effective May 20, to pursue new opportunities.

His decision to resign "did not result from any disagreement with the company on any matter relating to the company's operations, policies or practices," PacBio said in a From 8-K filed May 17 with the US Securities and Exchange Commission.

CEO Christian Henry will take over marketing responsibilities until a successor is appointed and Chris Seipert, VP of customer experience, will take over sales, service, and support responsibilities.

LynxDx: Steve Riggs, Spencer Heaton, Jeff Crays

Prostate screening test startup LynxDx said Steve Riggs has become president of the company. Additionally, Spencer Heaton has been named chief medical and commercial officer, and Jeff Crays has been named chief technology officer. In addition to being president of LynxDx, Riggs is the CEO of the Ann Arbor, Michigan-based company. Heaton, meanwhile, is a physician executive experienced in healthcare delivery, healthcare technology services, venture capital, and diagnostics development. Crays has 20 years of experience in emerging technology and business strategy. LynxDx was launched in 2020 and has developed the MyProstateScore, a noninvasive, urine-based test that detects the presence of two genetic biomarkers linked to prostate cancer.

NeoGenomics: Lynn Tetrault, Douglas Brown

NeoGenomics announced that it has appointed Lynn Tetrault as interim CEO and chair of the board of directors. Tetrault has been executive chair and principal executive officer of the company since March, when former CEO Mark Mallon stepped down, and has been overseeing the interim office of the CEO while NeoGenomics searches for a permanent CEO. 

Tetrault has been a board member since 2015, was the lead independent director from 2020 to 2021, and was appointed nonexecutive chair in 2021. She previously served in a variety of roles at AstraZeneca, including EVP of human resources and corporate affairs. She is also a nonexecutive director of Rhythm Pharmaceuticals.

NeoGenomics also announced that Douglas Brown, its chief strategy and corporate development officer, will be leaving the firm on May 27.

Genetic Signatures: Caroline Waldron

Australian-headquartered molecular diagnostics firm Genetic Signatures has appointed Caroline Waldron as a non-executive director. Waldron is currently a director of Resimac Group and AMA Group. She has executive experience in law, HR, marketing, risk, and internal audit, and has formal law training, including admittance to the Bar of England and Wales.

Curiox Biosystems: Don O'Neil

Curiox Biosystems, a Woburn, Massachusetts-based life sciences sample prep company, has appointed Don O'Neil as chief commercialization officer. O'Neil has more than 25 years of sales and marketing experience in life science research, pharmaceuticals, sequencing, and diagnostics, including stints with Illumina, Invitrogen, and Millipore. He has also previously served as senior VP of sales and strategic partnerships at Orflo, and chief commercial officer of Gemini Biosystems. He holds an MS in mechanical engineering from the University of California, San Diego and an MBA from Cornell University.

All of Us Research Program: Andrea Ramirez, Rachele Peterson

Andrea Ramirez has been appointed as chief data officer and Rachele Peterson as chief of staff for the National Institutes of Health's All of Us Research Program.

Ramirez was previously a physician scientist at Vanderbilt University Medical Center, where she also led the data science team at the All of Us Data and Research Center. She holds a medical degree from Duke University School of Medicine, an MS in clinical investigation from Vanderbilt University, and a BS in biochemistry from North Carolina State University.

Peterson comes to All of Us from Vibrent Health, where she was senior director of clinical research and served as principal investigator for multiple projects related to Vibrent's work with All of Us. Prior to that, she was the executive director and principal investigator of the University of Arizona and Banner Health All of Us Health Care Provider Organization. She holds an MS and an executive MBA from Arizona State University and a BA in public policy from the University of North Carolina at Chapel Hill.

National Academy of Sciences: Jay Shendure

Jay Shendure has been elected to the National Academy of Sciences. He is a professor of genome sciences at the University of Washington. He holds MD and PhD degrees from Harvard Medical School and is an investigator with the Howard Hughes Medical Institute, director of the Allen Discovery Center for Cell Lineage Tracing, and scientific director of the Brotman Baty Institute for Precision Medicine.

Quantum-Si: Patrick Schneider, Michael McKenna

Quantum-Si has named Patrick Schneider as president and chief operating officer, succeeding Michael McKenna who will remain as executive vice president, product development and operations.

Schneider was previously senior vice president of strategy, business development and innovation, and chair of the life science innovation board at Millipore Sigma. Before that he was vice president of R&D, business development and scientific affairs at Serologicals. He also cofounded Genome Biosciences and Integrated Cell Technologies.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.